Version · CLP
Version in force
Made by Regulation (EU) 2024/197 32024R0197 on EUR-Lex (external, EUR-Lex)
Version 28 of 31 recorded for CLP.
First seen by emendrix on , when it first read this version; that is not a legal date.
1 change in this version
Consolidated versions 02008R1272-20250201 → 02008R1272-20250901. v1 is the previous version, v2 this one.
What changed
Annex VI Harmonised classification and labelling for certain hazardous substances, Modified§
No explanation shipped — the difference between the two versions lies beyond the characters this stage can show, so no explanation was requested.
Each CAS and EC number in these tables links to its own page, which lists every entry that prints it across the acts this record holds.
28 entries added, 25 amended, 0 removed (1 of the amended differs only in spacing, dash forms or accents).
1 row carries no key and is not compared.
28 entries added
| Identifiers | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | |||||||
| Index No 015-204-00-5CAS 577705-90-9EC 479-100-5 | 015-204-00-5 | benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate | 479-100-5 | 577705-90-9 | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
| Index No 015-205-00-0CAS 75768-65-9EC 278-305-5 | 015-205-00-0 | benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) | 278-305-5 | 75768-65-9 | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
| Index No 015-206-00-6 | 015-206-00-6 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) | — | — | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
| Index No 015-207-00-1 | 015-207-00-1 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) | — | — | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
| Index No 015-208-00-7CAS 18755-43-6EC 242-555-3 | 015-208-00-7 | dimethyl propylphosphonate | 242-555-3 | 18755-43-6 | Muta. 1B Repr. 1B | H340 H360Df | GHS08 Dgr | H340 H360Df | |||
| Index No 050-034-00-5CAS 78-04-6EC 201-077-5 | 050-034-00-5 | dibutyltin maleate | 201-077-5 | 78-04-6 | Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 | H341 H360FD H330 H302 H372 (immune system) H314 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H330 H302 H372 (immune system) H314 | inhalation: ATE = 0,317 mg/L (dusts or mists) oral: ATE = 510 mg/kg bw | ||
| Index No 050-035-00-0CAS 818-08-6EC 212-449-1 | 050-035-00-0 | dibutyltin oxide | 212-449-1 | 818-08-6 | Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 | H341 H360FD H301 H372 (immune system) H315 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H301 H372 (immune system) H315 H318 | oral: ATE = 170 mg/kg bw | ||
| Index No 603-244-00-1 | 603-244-00-1 | reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane | — | — | Muta. 2 Repr. 1B | H341 H360F | GHS08 Dgr | H341 H360F | |||
| Index No 603-245-00-7CAS 3179-89-3EC 221-665-5 | 603-245-00-7 | 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol | 221-665-5 | 3179-89-3 | Skin Sens. 1 | H317 | GHS07 Wng | H317 | |||
| Index No 603-246-00-2CAS 647-42-7EC 211-477-1 | 603-246-00-2 | 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol | 211-477-1 | 647-42-7 | STOT RE 2 Aquatic Chronic 1 | H373 (teeth, bones) H410 | GHS08 GHS09 Wng | H373 (teeth, bones) H410 | M = 1 | ||
| Index No 604-099-00-7CAS 1478-61-1EC 216-036-7 | 604-099-00-7 | 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF | 216-036-7 | 1478-61-1 | Repr. 1B | H360F | GHS08 Dgr | H360F | |||
| Index No 604-100-00-0CAS 1119449-38-5CAS 127087-87-0CAS 14409-72-4CAS 20427-84-3CAS 26027-38-3CAS 26264-02-8CAS 27176-93-8CAS 27177-05-5CAS 27942-27-4CAS 27986-36-3CAS 68412-54-4CAS 7311-27-5CAS 9016-45-9EC 230-770-5EC 243-816-4EC 247-555-7EC 248-291-5EC 248-293-6EC 248-743-1EC 248-762-5EC 500-024-6EC 500-045-0EC 500-209-1EC 500-315-8 | 604-100-00-0 | nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] | 500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 — 230-770-5 248-743-1 247-555-7 248-293-6 — and others | 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 10 | ||
| Index No 606-155-00-6CAS 104-55-2CAS 14371-10-9EC 203-213-9 | 606-155-00-6 | cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] | 203-213-9 [1] - [2] | 104-55-2 [1] 14371-10-9 [2] | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,01 % | ||
| Index No 607-766-00-0CAS 2082-81-7EC 218-218-1 | 607-766-00-0 | tetramethylene dimethacrylate | 218-218-1 | 2082-81-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | |||
| Index No 607-767-00-6CAS 72869-86-4EC 276-957-5 | 607-767-00-6 | 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate | 276-957-5 | 72869-86-4 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | |||
| Index No 607-768-00-1CAS 109-16-0EC 203-652-6 | 607-768-00-1 | 2,2'-ethylenedioxydiethyl dimethacrylate | 203-652-6 | 109-16-0 | Skin Sens. 1B | H317 | GHS07 Wng | H317 | |||
| Index No 607-769-00-7CAS 42576-02-3EC 255-894-7 | 607-769-00-7 | bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate | 255-894-7 | 42576-02-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 | ||
| Index No 612-295-00-9CAS 1861-40-1EC 217-465-2 | 612-295-00-9 | benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine | 217-465-2 | 1861-40-1 | Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H315 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H315 H319 H317 H410 | M = 10 M = 10 | ||
| Index No 612-296-00-4CAS 99-97-8EC 202-805-4 | 612-296-00-4 | N,N-dimethyl-p-toluidine | 202-805-4 | 99-97-8 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 | H350 H332 H301 H373 (blood system, respiratory tract) H412 | GHS08 GHS06 Dgr | H350 H332 H301 H373 (blood system, respiratory tract) H412 | inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw | ||
| Index No 612-297-00-XCAS 729-43-1EC 211-979-0 | 612-297-00-X | 1-phenylethan-1-one (1-phenylethylidene)hydrazone | 211-979-0 | 729-43-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317 | |||
| Index No 612-298-00-5CAS 68953-84-4EC 273-227-8 | 612-298-00-5 | 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; | 273-227-8 | 68953-84-4 | Repr. 1B Skin Sens. 1 | H360FD H317 | GHS08 GHS07 Dgr | H360FD H317 | |||
| Index No 613-346-00-8CAS 59-89-2 | 613-346-00-8 | 4-nitrosomorpholine | — | 59-89-2 | Carc. 1B Muta. 2 STOT RE 1 | H350 H341 H372 (liver) | GHS08 Dgr | H350 H341 H372 (liver) | Carc. 1B; H350: C ≥ 0,001 % | ||
| Index No 613-347-00-3CAS 119446-68-3 | 613-347-00-3 | difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether | — | 119446-68-3 | Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H319 H410 | oral: ATE = 1450 mg/kg bw M = 10 M = 10 | ||
| Index No 613-348-00-9CAS 989-38-8EC 213-584-9 | 613-348-00-9 | 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 | 213-584-9 | 989-38-8 | Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H301 H318 H317 H410 | oral: ATE = 280 mg/kg bw M = 10 M = 1 | ||
| Index No 613-349-00-4CAS 822-36-6EC 212-497-3 | 613-349-00-4 | 4-methylimidazole | 212-497-3 | 822-36-6 | Carc. 1B Repr. 1B | H350 H360Fd | GHS08 Dgr | H350 H360Fd | |||
| Index No 615-051-00-XCAS 91-97-4EC 202-112-7 | 615-051-00-X | 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate | 202-112-7 | 91-97-4 | Carc. 2 Resp. Sens. 1 Skin Sens. 1A | H351 H334 H317 | GHS08 Dgr | H351 H334 H317 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
| Index No 616-241-00-5CAS 173159-57-4 | 616-241-00-5 | foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea | — | 173159-57-4 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1000 M = 100 | ||
| Index No 616-242-00-0CAS 137641-05-5 | 616-242-00-0 | picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide | — | 137641-05-5 | STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H373 (blood system, thyroid) H400 H410 | GHS08 GHS09 Wng | H373 (blood system, thyroid) H410 | M = 1000 M = 1000 | ||
25 entries amended
| Identifiers | Version | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||||
| Index No 006-015-00-9CAS 330-54-1EC 206-354-4 | Before | 006-015-00-9 | diuron (ISO);
| 206-354-4 | 330-54-1 | Carc. | GHS08
| M = | ||||
| After | 006-015-00-9 | diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea | 206-354-4 | 330-54-1 | Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H373 (blood system) H400 H410 | GHS08 GHS09 Dgr | H350 H373 (blood system) H410 | M = 100 M = 100 | |||
| Index No 015-203-00-XCAS 75980-60-8EC 278-355-8 | Before | 015-203-00-X | diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide | 278-355-8 | 75980-60-8 | Repr. | GHS08
| |||||
| After | 015-203-00-X | diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide | 278-355-8 | 75980-60-8 | Repr. 1B Skin Sens. 1B | H360Fd H317 | GHS08 GHS07 Dgr | H360Fd H317 | ||||
| Index No 016-001-00-4CAS 7783-06-4EC 231-977-3 | Before | 016-001-00-4 | hydrogen | 231-977-3 | 7783-06-4 | Flam. Gas | H220 H330 H400 | GHS02
| H220 H330 H400 | U | ||
| After | 016-001-00-4 | hydrogen sulphide, hydrogen sulfide | 231-977-3 | 7783-06-4 | Flam. Gas 1A Press. Gas Acute Tox. 2 Aquatic Acute 1 | H220 H330 H400 | GHS02 GHS06 GHS09 Dgr | H220 H330 H400 | inhalation: ATE = 440 ppmV (gases) | U | ||
| Index No 016-011-00-9CAS 7446-09-5EC 231-195-2 | Before | 016-011-00-9 | sulphur dioxide | 231-195-2 | 7446-09-5 | Press. Gas
Acute Tox. 3 | H331 H314 | GHS04 GHS06 GHS05 Dgr | H331 H314 | |||
| After | 016-011-00-9 | sulphur dioxide; sulfur dioxide | 231-195-2 | 7446-09-5 | Press. Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B | H331 H370 (respiratory system) (inhalation) H314 | GHS04 GHS06 GHS08 GHS05 Dgr | H331 H370 (respiratory system) (inhalation) H314 | inhalation: ATE = 1000 ppmV (gases) | U, 5 | ||
| Index No 017-004-00-3CAS 3811-04-9EC 223-289-7 | Before | 017-004-00-3 | potassium chlorate | 223-289-7 | 3811-04-9 | Ox. Sol. 1
Acute Tox. | H271
| GHS03
| H271
| |||
| After | 017-004-00-3 | potassium chlorate | 223-289-7 | 3811-04-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | oral: ATE = 100 mg/kg bw | |||
| Index No 017-005-00-9CAS 7775-09-9EC 231-887-4 | Before | 017-005-00-9 | sodium chlorate | 231-887-4 | 7775-09-9 | Ox. Sol. 1
Acute Tox. | H271
| GHS03
| H271
| |||
| After | 017-005-00-9 | sodium chlorate | 231-887-4 | 7775-09-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | oral: ATE = 100 mg/kg bw | |||
| Index No 082-013-00-1CAS 7439-92-1EC 231-100-4 | Before | 082-013-00-1 | lead powder; [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 %
M = | ||
| After | 082-013-00-1 | lead powder; [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100 | |||
| Index No 082-014-00-7CAS 7439-92-1EC 231-100-4 | Before | 082-014-00-7 | lead massive: [particle diameter ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. | H360FD H362 | GHS08 Dgr | H360FD H362 | |||
| After | 082-014-00-7 | lead massive: [particle diameter ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact.Aquatic Chronic 1 | H360FD H362H410 | GHS08 GHS09 Dgr | H360FD H362H410 | M = 10 | |||
| Index No 603-057-00-5CAS 100-51-6EC 202-859-9 | Before | 603-057-00-5 | benzyl alcohol | 202-859-9 | 100-51-6 | Acute Tox. 4 | GHS07 Wng | |||||
| After | 603-057-00-5 | benzyl alcohol | 202-859-9 | 100-51-6 | Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B | H302H319 H317 | GHS07 Wng | H302H319 H317 | oral: ATE = 1200 mg/kg bw | |||
| Index No 604-010-00-1CAS 108-46-3EC 203-585-2 | Before | 604-010-00-1 | resorcinol; 1,3-benzenediol | 203-585-2 | 108-46-3 | Acute Tox. 4 | H302
H319
| GHS07
GHS09
| H302
H319
| |||
| After | 604-010-00-1 | resorcinol; 1,3-benzenediol | 203-585-2 | 108-46-3 | Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1B Aquatic Acute 1 | H302 H370 (nervous system) H315 H319 H317 H400 | GHS07 GHS08 GHS09 Dgr | H302 H370 (nervous system) H315 H319 H317 H400 | oral: ATE = 500 mg/kg bw M = 1 | |||
| Index No 604-074-00-0CAS 79-94-7EC 201-236-9 | Before | 604-074-00-0 | 201-236-9 | 79-94-7 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09
| H410 | ||||
| After | 604-074-00-0 | 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A | 201-236-9 | 79-94-7 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Dgr | H350 H410 | ||||
| Index No 606-034-00-8CAS 21087-64-9EC 244-209-7 | Before | 606-034-00-8 | metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one | 244-209-7 | 21087-64-9 | Acute Tox. 4 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | |||
| After | 606-034-00-8 | metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one | 244-209-7 | 21087-64-9 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (blood system) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (blood system) H410 | oral: ATE = 320 mg/kg bw M = 10 M = 10 | |||
| Index No 607-032-00-XCAS 140-88-5EC 205-438-8 | Before | 607-032-00-X | ethyl acrylate | 205-438-8 | 140-88-5 | Flam. Liq. 2
Acute Tox. | H225
| GHS02
| H225
| Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % | D | |
| After | 607-032-00-X | ethyl acrylate | 205-438-8 | 140-88-5 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | inhalation: ATE = 9 mg/L (vapours) dermal: ATE = 1800 mg/kg bw oral: ATE = 1120 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % | D | ||
| Index No 607-034-00-0CAS 96-33-3EC 202-500-6 | Before | 607-034-00-0 | methyl acrylate; methyl propenoate | 202-500-6 | 96-33-3 | Flam. Liq. 2
Acute Tox. | H225
| GHS02
| H225
| D | ||
| After | 607-034-00-0 | methyl acrylate; methyl propenoate | 202-500-6 | 96-33-3 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1100 mg/kg bw oral: ATE = 500 mg/kg bw | D | ||
| Index No 607-223-00-8CAS 118712-89-3EC 405-060-5 | Before | 607-223-00-8 | transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl | 405-060-5 | 118712-89-3 | GHS07 GHS09 Wng | ||||||
| After | 607-223-00-8 | transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 405-060-5 | 118712-89-3 | Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H370 (nervous system) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H370 (nervous system) H410 | EUH066 | oral: ATE = 580 mg/kg bw M = 1000 M = 1000 | ||
| Index No 607-246-00-3CAS 96-05-9EC 202-473-0 | Before | 607-246-00-3 | allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester | 202-473-0 | 96-05-9 | Flam. Liq. 3
Acute Tox. 3 | H226
| GHS02 GHS06 GHS09 Dgr | H226
| |||
| After | 607-246-00-3 | allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester | 202-473-0 | 96-05-9 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 | H226 H330 H311 H302 H400 | GHS02 GHS06 GHS09 Dgr | H226 H330 H311 H302 H400 | inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw | |||
| Index No 612-004-00-5CAS 121-44-8EC 204-469-4 | Before | 612-004-00-5 | triethylamine | 204-469-4 | 121-44-8 | Flam. Liq. 2
Acute Tox. | H225
| GHS02
GHS05
| H225
| STOT SE 3; H335: C ≥ 1 % | ||
| After | 612-004-00-5 | triethylamine | 204-469-4 | 121-44-8 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1AEye Dam. 1 | H225 H331 H311 H301 H314H318 | GHS02 GHS06 GHS05 Dgr | H225 H331 H311 H301 H314 | inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 % | |||
| Index No 612-049-00-0CAS 111-92-2CAS 626-23-3EC 203-921-8EC 210-937-9 | Before | 612-049-00-0 | 203-921-8 | 111-92-2 | Flam. Liq. 3
Acute Tox. | H226
| GHS02
| H226
| ||||
| After | 612-049-00-0 | di-n-butylamine | 203-921-8 | 111-92-2 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 | H226 H330 H311 H301 H314 H318 | GHS02 GHS06 GHS05 Dgr | H226 H330 H311 H301 H314 | EUH 071 | inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw | ||
| Index No 612-056-00-9CAS 121-72-2CAS 609-72-3CAS 99-97-8EC 202-805-4EC 204-495-6EC 210-199-8 | Before | 612-056-00-9 | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Dgr | H331 H311 H301 H373 ** H412 | * | C | ||||
| After | 612-056-00-9 | N,N-dimethyl-m-toluidine; [1] N,N-dimethyl-o-toluidine [2] | 204-495-6 [1] 210-199-8 [2] | 121-72-2 [1] 609-72-3 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Dgr | H331 H311 H301 H373 ** H412 | * | C | ||
| Index No 613-088-00-6CAS 2634-33-5EC 220-120-9 | Before | 613-088-00-6 | 220-120-9 | 2634-33-5 | Acute Tox. 4 | H302 H315 H318 H317 H400 | GHS05
| H302
H315
H318
H317
| Skin Sens. | |||
| After | 613-088-00-6 | 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one | 220-120-9 | 2634-33-5 | Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1Aquatic Chronic 1 | H330 H302 H315 H318 H317 H400H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H315 H318 H317 H410 | inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 %M = 1 M = 1 | |||
| Index No 613-127-00-7CAS 24307-26-4EC 246-147-6 | Before | 613-127-00-7 | 246-147-6 | 24307-26-4 | Acute Tox. 4 | |||||||
| After | 613-127-00-7 | mepiquat chloride(ISO); 1,1-dimethylpiperidinium chloride | 246-147-6 | 24307-26-4 | Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 | H332 H301 H412 | GHS06 Dgr | H332 H301 H412 | inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw | |||
| Index No 613-307-00-5CAS 210880-92-5EC 433-460-1 | Before | 613-307-00-5 | clothianidin (ISO);
| 210880-92-5 | Acute Tox. 4 | H302 H400 H410 | GHS07
GHS09
| H302 H410 | ||||
| After | 613-307-00-5 | clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine | 433-460-1 | 210880-92-5 | Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H302 H370 (nervous system) H400 H410 | GHS08 GHS07 GHS09 Dgr | H361f H302 H370 (nervous system) H410 | oral: ATE = 390 mg/kg bw M = 10 M = 100 | |||
| Index No 616-035-00-5CAS 166900-80-7CAS 57966-95-7EC 261-043-0 | Before | 616-035-00-5 | cymoxanil (ISO);
| 261-043-0 | 57966-95-7 | Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361fd
H302
H373 | GHS08 GHS07 GHS09 Wng | H361fd
H302
H373 | M = 1 M = 1 | ||
| After | 616-035-00-5 | cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] | 261-043-0[1] - [2] | 57966-95-7[1] 166900-80-7 [2] | Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H373 (blood system, thymus, eyes) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361fd H302 H373 (blood system, thymus, eyes) H317 H410 | oral: ATE = 360 mg/kg bw M = 1 M = 1 | |||
| Index No 616-104-00-XCAS 71626-11-4EC 275-728-7 | Before | 616-104-00-X | benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate | 275-728-7 | 71626-11-4 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | |||
| After | 616-104-00-X | benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate | 275-728-7 | 71626-11-4 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | oral: ATE = 1000 mg/kg bw M = 1 M = 1 | |||
1 entry differs only in spacing, dash forms or accents
| Identifiers | Version | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||||
| Index No 616-240-00-XCAS 881685-58-1 | Before | 616-240-00-X | Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam | — | 881685-58-1 | Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H360D H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H351
H360D
| Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10 | ||
| After | 616-240-00-X | Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam | — | 881685-58-1 | Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H360D H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H351 H360D H317H410 | Repr. 1B; H360D: C ≥ 3 % M = 10 M = 10 | |||
Text from EUR-Lex, before and after
Previous version, in force 1 February 2025 02008R1272-20250201 → this version, in force 1 September 2025 02008R1272-20250901
compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere
ANNEX VI
Harmonised classification and labelling for certain hazardous substances
Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3.
… 908 unchanged lines …
Wng H302
H335
H317
H410 006-015-00-9 diuron (ISO);
3-(3,4-dichlorophenyl)-1,1-dimethylurea 206-354-4 330-54-1 Carc. 2
Acute Tox. 4 *
STOT RE 2 * H410 006-015-00-9 diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea 206-354-4 330-54-1 Carc. 1B
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H302
H373** Aquatic Chronic 1 H350
H373 (blood system)
H400
H410 GHS08
GHS07
GHS09
Wng H351
H302
H373** H410 M = 10 006-016-00-4 propoxur (ISO); Dgr H350
H373 (blood system)
H410 M = 100
M = 100 006-016-00-4 propoxur (ISO);
2-isopropyloxyphenyl N-methylcarbamate;
2-isopropoxyphenyl methylcarbamate 204-043-8 114-26-1 Acute Tox. 3 * Aquatic Acute 1
Aquatic Chronic 1 H301
… 3,671 unchanged lines …
H410 GHS07
GHS09
Wng H317
H410 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 2 H361f (causing atrophy of the testes) GHS08
Wng H361f (causing atrophy of the testes) 016-001-00-4 hydrogen sulphide 231-977-3 7783-06-4 Flam. Gas 1 H410 015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 1B
Skin Sens. 1B H360Fd
H317 GHS08
GHS07
Dgr H360Fd
H317 015-204-00-5 benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate 479-100-5 577705-90-9 Repr. 1B H360F GHS08
Dgr H360F 015-205-00-0 benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) 278-305-5 75768-65-9 Repr. 1B H360F GHS08
Dgr H360F 015-206-00-6 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) — — Repr. 1B H360F GHS08
Dgr H360F 015-207-00-1 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) — — Repr. 1B H360F GHS08
Dgr H360F 015-208-00-7 dimethyl propylphosphonate 242-555-3 18755-43-6 Muta. 1B
Repr. 1B H340
H360Df GHS08
Dgr H340
H360Df 016-001-00-4 hydrogen sulphide, hydrogen sulfide 231-977-3 7783-06-4 Flam. Gas 1A
Press. Gas
Acute Tox. 2 * Acute Tox. 2
Aquatic Acute 1 H220
H330
H400 GHS02
GHS04
GHS06
GHS09
Dgr H220
H330
H400 U H400 inhalation: ATE = 440 ppmV (gases) U
016-002-00-X barium sulphide 244-214-4 21109-95-5 Acute Tox. 4 *
Acute Tox. 4 *
Aquatic Acute 1 H332
… 73 unchanged lines …
GHS09
Dgr H301
H314
H400 EUH031 016-011-00-9 sulphur dioxide 231-195-2 7446-09-5 Press. Gas
Acute Tox. 3 *
Skin Corr. 1B H331 H400 EUH031 016-011-00-9 sulphur dioxide; sulfur dioxide 231-195-2 7446-09-5 Press. Gas
Acute Tox. 3
STOT SE 1
Skin. Corr. 1B H331
H370 (respiratory system) (inhalation)
H314 GHS04
GHS06
GHS08
GHS05
Dgr H331
H314 * U5 H370 (respiratory system) (inhalation)
H314 inhalation: ATE = 1000 ppmV (gases) U, 5
016-012-00-4 disulphur dichloride;
sulfur monochloride 233-036-2 10025-67-9 Acute Tox. 3 *
Acute Tox. 4 *
… 621 unchanged lines …
H332
H302
H411 017-004-00-3 potassium chlorate 223-289-7 3811-04-9 Ox. Sol. 1
Acute Tox. 4 *
Acute Tox. 4 *
Aquatic Chronic 2 H271
H332
H302
H411 GHS03
GHS07
GHS09 Acute Tox. 3 H271
H301 GHS03
GHS06
Dgr H271
H332
H302
H411 017-005-00-9 sodium chlorate 231-887-4 7775-09-9 Ox. Sol. 1
Acute Tox. 4 *
Aquatic Chronic 2 H271
H302
H411 GHS03
GHS07
GHS09 H301 oral: ATE = 100 mg/kg bw 017-005-00-9 sodium chlorate 231-887-4 7775-09-9 Ox. Sol. 1
Acute Tox. 3 H271
H301 GHS03
GHS06
Dgr H271
H302
H411 017-006-00-4 perchloric acid … % 231-512-4 7601-90-3 Ox. Liq. 1 H301 oral: ATE = 100 mg/kg bw 017-006-00-4 perchloric acid … % 231-512-4 7601-90-3 Ox. Liq. 1
Skin Corr. 1A H271
H314 GHS03
GHS05
… 3,476 unchanged lines …
H372 (immune system) GHS08
Dgr H341
H360FD
H372 (immune system) 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B H372 (immune system) 050-034-00-5 dibutyltin maleate 201-077-5 78-04-6 Muta. 2
Repr. 1B
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Skin Corr. 1
Eye Dam. 1 H341
H360FD
H330
H302
H372 (immune system)
H314
H318 GHS08
GHS06
GHS05
Dgr H341
H360FD
H330
H302
H372 (immune system)
H314 inhalation:
ATE = 0,317 mg/L (dusts or mists)
oral:
ATE = 510 mg/kg bw 050-035-00-0 dibutyltin oxide 212-449-1 818-08-6 Muta. 2
Repr. 1B
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1 H341
H360FD
H301
H372 (immune system)
H315
H318 GHS08
GHS06
GHS05
Dgr H341
H360FD
H301
H372 (immune system)
H315
H318 oral:
ATE = 170 mg/kg bw 051-001-00-8 antimony trichloride 233-047-2 10025-91-9 Skin Corr. 1B
Aquatic Chronic 2 H314
H411 GHS05
GHS09
… 787 unchanged lines …
GHS09
Wng H302
H373**
H411 082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A H411 082-013-00-1 lead powder;
[particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A
Lact.
Aquatic Acute 1
Aquatic Chronic 1 H360FD
H362
H400
H410 GHS08
GHS09
Dgr H360FD H362
H410 Repr. 1A; H360D: C ≥ 0,03 %
M = 1
M = 10 082-014-00-7 lead massive:
[particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A
Lact. H360FD
H362 GHS08
Dgr H360FD
H362 092-001-00-8 uranium 231-170-6 7440-61-1 Acute Tox. 2 * H362
H410 Repr. 1A;
H360D: C ≥ 0,03 %
M = 10
M = 100 082-014-00-7 lead massive:
[particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A
Lact.
Aquatic Chronic 1 H360FD
H362
H410 GHS08
GHS09
Dgr H360FD
H362
H410 M = 10 092-001-00-8 uranium 231-170-6 7440-61-1 Acute Tox. 2 *
Acute Tox. 2 *
STOT RE 2 *
Aquatic Chronic 4 H330
… 3,002 unchanged lines …
H315
H317
H411 C
603-057-00-5 benzyl alcohol 202-859-9 100-51-6 Acute Tox. 4 * Acute Tox. 4 * H332
H302 GHS07
Wng H332
H302 603-058-00-0 1,3-propylene oxide 207-964-3 503-30-0 Flam. Liq. 2 603-057-00-5 benzyl alcohol 202-859-9 100-51-6 Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1B H302
H319
H317 GHS07
Wng H302
H319
H317 oral: ATE = 1200 mg/kg bw 603-058-00-0 1,3-propylene oxide 207-964-3 503-30-0 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * H225
H332
H312
… 1,137 unchanged lines …
Muta. 2 H350
H341 GHS08
Dgr H350
H341 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 H341 603-244-00-1 reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane — — Muta. 2
Repr. 1B H341
H360F GHS08
Dgr H341
H360F 603-245-00-7 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol 221-665-5 3179-89-3 Skin Sens. 1 H317 GHS07
Wng H317 603-246-00-2 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol 211-477-1 647-42-7 STOT RE 2
Aquatic Chronic 1 H373 (teeth, bones)
H410 GHS08
GHS09
Wng H373 (teeth, bones)
H410 M = 1 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2
Acute Tox. 3 * Acute Tox. 3 *
Acute Tox. 3 * STOT RE 2 *
Skin Corr. 1B H341
… 158 unchanged lines …
H332
H312
H302
H412 * 604-010-00-1 resorcinol; 1,3-benzenediol 203-585-2 108-46-3 Acute Tox. 4 * H412 * 604-010-00-1 resorcinol; 1,3-benzenediol 203-585-2 108-46-3 Acute Tox. 4
STOT SE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Irrit. 2 Skin Sens. 1B
Aquatic Acute 1 H302
H370 (nervous system)
H315
H319
H317
H400 GHS07
GHS08
GHS09
Dgr H302
H370 (nervous system)
H315
H400 GHS07
GHS09
Wng H302
H319
H315
H400 * 604-011-00-7 2,4-dichlorophenol 204-429-6 120-83-2 Acute Tox. 3 * H317
H400 oral: ATE = 500 mg/kg bw
M = 1 604-011-00-7 2,4-dichlorophenol 204-429-6 120-83-2 Acute Tox. 3 *
Acute Tox. 4 *
Skin Corr. 1B
Aquatic Chronic 2 H311
… 455 unchanged lines …
GHS09
Dgr H351
H360F*** H317
H410 604-074-00-0 tetrabromobisphenol-A; 2,2', 6,6'-tetrabromo-4,4'-isopropylidenediphenol 201-236-9 79-94-7 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 604-075-00-6 4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol 205-426-2 140-66-9 Skin Irrit. 2 H410 604-074-00-0 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A 201-236-9 79-94-7 Carc. 1B
Aquatic Acute 1
Aquatic Chronic 1 H350
H400
H410 GHS08
GHS09
Dgr H350
H410 604-075-00-6 4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol 205-426-2 140-66-9 Skin Irrit. 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1 H315
… 188 unchanged lines …
H373 (liver)
H317 oral:
ATE = 500 mg/kg bw 604-098-00-1 4,4'-sulphonyldiphenol; bisphenol S 201-250-5 80-09-1 Repr. 1B H360FD GHS08
Dgr H360FD 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Dgr H360FD 604-099-00-7 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF 216-036-7 1478-61-1 Repr. 1B H360F GHS08
Dgr H360F 604-100-00-0 nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] 500-315-8
500-024-6
500-045-0
500-209-1
248-762-5
243-816-4
248-291-5
—
230-770-5 248-743-1 247-555-7 248-293-6
—
and others 127087-87-0
9016-45-9
26027-38-3
68412-54-4
27986-36-3
20427-84-3
27176-93-8
1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 M = 1
M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2
Acute Tox. 3* Acute Tox. 3* Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1 H350
… 603 unchanged lines …
H302
H319
H315
H411 606-034-00-8 metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one 244-209-7 21087-64-9 Acute Tox. 4 * Aquatic Acute 1 H411 606-034-00-8 metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one 244-209-7 21087-64-9 Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H302
H373 (blood system)
H400
H410 GHS07
GHS08
GHS09
Wng H302
H410 M=10 606-035-00-3 chloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one; pyrazon 216-920-2 1698-60-8 Skin Sens. 1 H373 (blood system)
H410 oral: ATE = 320 mg/kg bw
M = 10
M = 10 606-035-00-3 chloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-(2H)-one; pyrazon 216-920-2 1698-60-8 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
H400
… 584 unchanged lines …
H410 oral:
ATE = 500 mg/kg bw
M = 10
M = 10 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal;
cinnamic aldehyde; cinnamal; [1]
(2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07
Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05
Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 %
Skin Irrit. 2; H315: 2 % ≤C
< 10 %
… 253 unchanged lines …
H332 607-031-00-4 butyl butyrate 203-656-8 109-21-7 Flam. Liq. 3 H226 GHS02
Wng H226 C
607-032-00-X ethyl acrylate 205-438-8 140-88-5 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 *
Acute Tox. 4 *
Eye Irrit. 2 Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1 H225
H332 H331
H312
H302
H319
H335
H315
H319
H317 GHS02
GHS07 GHS06
Dgr H225
H332 H331
H312
H302
H319
H335
H315
H317 Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % D H319
H317 inhalation: ATE = 9 mg/L (vapours)
dermal: ATE = 1800 mg/kg bw
oral: ATE = 1120 mg/kg bw
STOT SE 3; H335: C ≥ 5 %
Skin Irrit. 2; H315: C ≥ 5 %
Eye Irrit. 2; H319: C ≥ 5 % D
607-033-00-5 n-butyl methacrylate 202-615-1 97-88-1 Flam. Liq. 3
Eye Irrit. 2
STOT SE 3
Skin Irrit. 2
Skin Sens. 1 H226
H319
H335
H315
H317 GHS02
GHS07
Wng H226
H319
H335
H315
H317 D
607-034-00-0 methyl acrylate; methyl propenoate 202-500-6 96-33-3 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 *
Acute Tox. 4 *
Eye Irrit. 2 607-034-00-0 methyl acrylate;
methyl propenoate 202-500-6 96-33-3 Flam. Liq. 2
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1 H225
H332 H331
H312
H302
H319
H335
H315
H319
H317 GHS02
GHS07 GHS06
Dgr H225
H332 H331
H312
H302
H319
H335
H315
H317 D H319
H317 inhalation: ATE = 3 mg/L (vapours)
dermal: ATE = 1100 mg/kg bw
oral: ATE = 500 mg/kg bw D
607-035-00-6 methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate 201-297-1 80-62-6 Flam. Liq. 2
STOT SE 3
Skin Irrit. 2
… 1,546 unchanged lines …
H411 GHS07
GHS09
Wng H317
H411 607-223-00-8 transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl trans-2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate 405-060-5 118712-89-3 Skin Irrit. 2 H411 607-223-00-8 transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 405-060-5 118712-89-3 Carc. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1 H315 Aquatic Chronic 1 H351
H302
H370 (nervous system)
H400
H410 GHS07 H410 GHS08
GHS07
GHS09
Wng H315
H410 607-224-00-3 methyl 2-(3-nitrobenzylidene)acetoacetate 405-270-7 39562-17-9 Skin Sens. 1 Wng H351
H302
H370 (nervous system)
H410 EUH066 oral: ATE = 580 mg/kg bw
M = 1000
M = 1000 607-224-00-3 methyl 2-(3-nitrobenzylidene)acetoacetate 405-270-7 39562-17-9 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
H400
… 202 unchanged lines …
H315
H317
H411 D
607-246-00-3 allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester 202-473-0 96-05-9 Flam. Liq. 3
Acute Tox. 3 *
Acute Tox. 4 *
Acute Tox. 4 * Aquatic Acute 1 H226
H331
H312 607-246-00-3 allyl methacrylate;
2-methyl-2-propenoic acid 2-propenyl ester 202-473-0 96-05-9 Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 4
Aquatic Acute 1 H226
H330
H311
H302
H400 GHS02
GHS06
GHS09
Dgr H226
H331
H312 H330
H311
H302
H400 607-247-00-9 dodecyl methacrylate 205-570-6 142-90-5 STOT SE 3 H335 GHS07 H400 inhalation: ATE = 1,5 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 400 mg/kg bw 607-247-00-9 dodecyl methacrylate 205-570-6 142-90-5 STOT SE 3 H335 GHS07
Wng H335 STOT SE 3; H335: C ≥ 10 % 607-248-00-4 naptalam-sodium (ISO); sodium N-naphth-1-ylphthalamate 205-073-4 132-67-2 Acute Tox. 4 * H302 GHS07
Wng H302 607-249-00-X (1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)] diacrylate 256-032-2 42978-66-5 Eye Irrit. 2
STOT SE 3
… 2,769 unchanged lines …
GHS07
Dgr H360FD
H319 607-765-00-5 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid — — Repr. 1B H360FD GHS08
Dgr H360FD 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Dgr H360FD 607-766-00-0 tetramethylene dimethacrylate 218-218-1 2082-81-7 Skin Sens. 1B H317 GHS07
Wng H317 607-767-00-6 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate 276-957-5 72869-86-4 Skin Sens. 1B H317 GHS07
Wng H317 607-768-00-1 2,2'-ethylenedioxydiethyl dimethacrylate 203-652-6 109-16-0 Skin Sens. 1B H317 GHS07
Wng H317 607-769-00-7 bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate 255-894-7 42576-02-3 Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1 H302
H400
H410 GHS07
GHS09
Wng H302
H410 oral:
ATE = 1500 mg/kg bw
M = 1000
M = 1000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *
Eye Irrit. 2 H225
H332
… 2,640 unchanged lines …
H312
H302
H314 STOT SE 3; H335: C ≥ 1 % 612-004-00-5 triethylamine 204-469-4 121-44-8 Flam. Liq. 2
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 *
Skin Corr. 1A H225
H332
H312
H302
H314 GHS02 Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1A
Eye Dam. 1 H225
H331
H311
H301
H314
H318 GHS02
GHS06
GHS05
GHS07
Dgr H225
H332
H312
H302
H314 STOT SE 3; H335: C ≥ 1 % 612-005-00-0 butylamine 203-699-2 109-73-9 Flam. Liq. 2 H331
H311
H301
H314 inhalation: ATE = 7,2 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 % 612-005-00-0 butylamine 203-699-2 109-73-9 Flam. Liq. 2
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 *
… 624 unchanged lines …
H332
H312
H302
H314 STOT SE 3; H335: C ≥ 1 % 612-049-00-0 di-n-butylamine; [1]
di-sec-butylamine [2] 203-921-8 [1]
210-937-9 [2] 111-92-2 [1]
626-23-3 [2] Flam. Liq. 3
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 * H226
H332
H312
H302 GHS02
GHS07
Wng H226
H332
H312
H302 612-050-00-6 cyclohexylamine 203-629-0 108-91-8 Flam. Liq. 3 H314 STOT SE 3; H335: C ≥ 1 % 612-049-00-0 di-n-butylamine 203-921-8 111-92-2 Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1 H226
H330
H311
H301
H314
H318 GHS02
GHS06
GHS05
Dgr H226
H330
H311
H301
H314 EUH 071 inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw
oral: ATE = 220 mg/kg bw 612-050-00-6 cyclohexylamine 203-629-0 108-91-8 Flam. Liq. 3
Repr. 2
Acute Tox. 4 *
Acute Tox. 4 *
… 98 unchanged lines …
H301
H373 **
H412 C
612-056-00-9 N,N-dimethyl-p-toluidine; [1] N,N-dimethyl-m-toluidine; [2] N,N-dimethyl-o-toluidine [3] 202-805-4 [1]
204-495-6 [2]
210-199-8 [3] 99-97-8 [1]
121-72-2 [2]
609-72-3 [3] Acute Tox. 3 *
Acute Tox. 3 *
Acute Tox. 3 *
STOT RE 2 *
Aquatic Chronic 3 H331 612-056-00-9 N,N-dimethyl-m-toluidine; [1]
N,N-dimethyl-o-toluidine [2] 204-495-6 [1] 210-199-8 [2] 121-72-2 [1] 609-72-3 [2] Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 H331
H311
H301
H373 **
H412 GHS06
GHS08 H412 GHS06 GHS08
Dgr H331
H311
H301
… 2,701 unchanged lines …
GHS09
Dgr H314
H410 EUH071 M = 100
M = 1000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 M = 1000 612-295-00-9 benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine 217-465-2 1861-40-1 Carc. 2
Repr. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H351
H361d
H315
H319
H317
H400
H410 GHS08
GHS07
GHS09
Wng H351
H361d
H315
H319
H317
H410 M = 10
M = 10 612-296-00-4 N,N-dimethyl-p-toluidine 202-805-4 99-97-8 Carc. 1B
Acute Tox. 4
Acute Tox. 3
STOT RE 2
Aquatic Chronic 3 H350
H332
H301
H373 (blood system, respiratory tract)
H412 GHS08
GHS06
Dgr H350
H332
H301
H373 (blood system, respiratory tract)
H412 inhalation:
ATE = 1,4 mg/L (dusts or mists)
oral:
ATE = 140 mg/kg bw 612-297-00-X 1-phenylethan-1-one (1-phenylethylidene)hydrazone 211-979-0 729-43-1 Skin Sens. 1 H317 GHS07
Wng H317 612-298-00-5 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; 273-227-8 68953-84-4 Repr. 1B
Skin Sens. 1 H360FD
H317 GHS08
GHS07
Dgr H360FD
H317 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2
Carc. 1B
Muta. 1B
Acute Tox. 2 *
… 875 unchanged lines …
H302
H319
H315
H412 613-088-00-6 1,2-benzisothiazol-3(2H)-one;1,2-benzisothiazolin-3-one 220-120-9 2634-33-5 Acute Tox. 4 * H412 613-088-00-6 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one 220-120-9 2634-33-5 Acute Tox. 2
Acute Tox. 4
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1 H302 Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1 H330
H302
H315
H318
H317
H400 GHS05
GHS07 H400
H410 GHS06
GHS05
GHS09
Dgr H302 Dgr H330
H302
H315
H318
H317
H400 Skin Sens. 1; H317: C≥0,05 % 613-089-00-1 diquat dibromide; [1]diquat dichloride; [2]6,7-dihydrodipyrido[1,2-α:2',1'- c]pyrazinediylium dihydroxide [3] 201-579-4 [1] H410 inhalation:
ATE = 0,21 mg/L (dusts or mists)
oral: ATE = 450 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,036 %
M = 1
M = 1 613-089-00-1 diquat dibromide; [1]diquat dichloride; [2]6,7-dihydrodipyrido[1,2-α:2',1'- c]pyrazinediylium dihydroxide [3] 201-579-4 [1]
223-714-6 [2]
301-467-6 [3] 85-00-7 [1]
4032-26-2 [2]
… 321 unchanged lines …
Aquatic Chronic 3 H319
H412 GHS07
Wng H319
H412 613-127-00-7 1,1-dimethylpiperidinium chloride; mepiquat chloride 246-147-6 24307-26-4 Acute Tox. 4 *
Aquatic Chronic 3 H302
H412 GHS07
Wng H302
H412 613-128-00-2 prochloraz (ISO);N-propyl-N-[2-(2,4,6-trichlorop henoxy)ethyl]-1H-imidazole-1- carboxamide 266-994-5 67747-09-5 Acute Tox. 4 * Aquatic Acute 1 H412 613-127-00-7 mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride 246-147-6 24307-26-4 Acute Tox. 4
Acute Tox. 3
Aquatic Chronic 3 H332
H301
H412 GHS06
Dgr H332
H301
H412 inhalation: ATE = 2,8 mg/L (dusts or mists)
oral:
ATE = 270 mg/kg bw 613-128-00-2 prochloraz (ISO);N-propyl-N-[2-(2,4,6-trichlorop henoxy)ethyl]-1H-imidazole-1- carboxamide 266-994-5 67747-09-5 Acute Tox. 4 * Aquatic Acute 1
Aquatic Chronic 1 H302
H400
H410 GHS07
… 1,218 unchanged lines …
GHS09
Wng H302
H317
H411 613-307-00-5 clothianidin (ISO);
3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine — 210880-92-5 Acute Tox. 4 * H411 613-307-00-5 clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine 433-460-1 210880-92-5 Repr. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1 H302 Aquatic Chronic 1 H361f
H302
H370 (nervous system)
H400
H410 GHS07 H410 GHS08
GHS07
GHS09
Wng H302
H410 M=10 613-308-00-0 2-amino-5-methylthiazole 423-800-5 7305-71-7 Acute Tox. 4 * Dgr H361f
H302
H370 (nervous system)
H410 oral: ATE = 390 mg/kg bw
M = 10
M = 100 613-308-00-0 2-amino-5-methylthiazole 423-800-5 7305-71-7 Acute Tox. 4 *
STOT RE 2 *
Aquatic Acute 1
Aquatic Chronic 1 H302
… 439 unchanged lines …
STOT RE 2 H351
H373 (urinary tract) GHS08
Wng H351
H373 (urinary tract) 614-001-00-4 nicotine (ISO); H373 (urinary tract) 613-346-00-8 4-nitrosomorpholine — 59-89-2 Carc. 1B
Muta. 2
STOT RE 1 H350
H341
H372 (liver) GHS08
Dgr H350
H341
H372 (liver) Carc. 1B; H350: C ≥ 0,001 % 613-347-00-3 difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether — 119446-68-3 Carc. 2
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H302
H319
H400
H410 GHS08
GHS07
GHS09
Wng H351
H302
H319
H410 oral:
ATE = 1450 mg/kg bw
M = 10
M = 10 613-348-00-9 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 213-584-9 989-38-8 Acute Tox. 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H301
H318
H317
H400
H410 GHS06
GHS05
GHS09
Dgr H301
H318
H317
H410 oral:
ATE = 280 mg/kg bw
M = 10
M = 1 613-349-00-4 4-methylimidazole 212-497-3 822-36-6 Carc. 1B
Repr. 1B H350
H360Fd GHS08
Dgr H350
H360Fd 614-001-00-4 nicotine (ISO);
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
… 786 unchanged lines …
H334
H317
H412 inhalation:
ATE = 0,27 mg/L (dusts or mists) 616-001-00-X N, N-dimethylformamide; ATE = 0,27 mg/L (dusts or mists) 615-051-00-X 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate 202-112-7 91-97-4 Carc. 2
Resp. Sens. 1
Skin Sens. 1A H351
H334
H317 GHS08
Dgr H351
H334
H317 Skin Sens. 1A; H317: C ≥ 0,001 % 616-001-00-X N, N-dimethylformamide;
dimethyl formamide 200-679-5 68-12-2 Repr. 1B
Acute Tox. 4 *
Acute Tox. 4 *
… 269 unchanged lines …
Dgr H301
H312
H410 616-034-00-X pyracarbolid; (ISO);
3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide 246-419-4 24691-76-7 Aquatic Chronic 3 H412 — H412 616-035-00-5 cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide 261-043-0 57966-95-7 Repr. 2 3,4-dihydro-6-methyl-2H-pyran-5-carboxanilide 246-419-4 24691-76-7 Aquatic Chronic 3 H412 — H412 616-035-00-5 cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1]
(2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] 261-043-0 [1]
- [2] 57966-95-7 [1]
166900-80-7 [2] Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H361fd
H302
H373 (blood, thymus) H373 (blood system, thymus, eyes)
H317
H400
H410 GHS08
GHS07
GHS09
Wng H361fd
H302
H373 (blood, thymus) H373 (blood system, thymus, eyes)
H317
H410 M = 1
M = 1 616-036-00-0 2-chloracetamide 201-174-2 79-07-2 Repr. 2 H410 oral: ATE = 360 mg/kg bw
M = 1
M = 1 616-036-00-0 2-chloracetamide 201-174-2 79-07-2 Repr. 2
Acute Tox. 3 *
Skin Sens. 1 H361f *** H301
H317 GHS06
… 287 unchanged lines …
H410 GHS07
GHS09
Wng H317
H410 616-104-00-X benalaxyl (ISO);
methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate 275-728-7 71626-11-4 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 616-105-00-5 chlorotoluron (ISO); H410 616-104-00-X benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate 275-728-7 71626-11-4 Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1 H302
H400
H410 GHS07
GHS09
Wng H302
H410 oral: ATE = 1000 mg/kg bw
M = 1
M = 1 616-105-00-5 chlorotoluron (ISO);
3-(3-chloro-p-tolyl)-1,1-dimethylurea 239-592-2 15545-48-9 Carc. 2
Repr. 2
Aquatic Acute 1
… 687 unchanged lines …
GHS09
Dgr H351
H360D
H317
H410 Repr. 1B; H360D: H317H410 Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 M = 10 616-241-00-5 foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea — 173159-57-4 Carc. 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H400
H410 GHS08
GHS09
Wng H351
H410 M = 1000
M = 100 616-242-00-0 picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide — 137641-05-5 STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H373 (blood system, thyroid)
H400
H410 GHS08
GHS09
Wng H373 (blood system, thyroid)
H410 M = 1000
M = 1000 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242
H225
H341 GHS02
GHS08
… 24,970 unchanged lines …
S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N
R: 50/53
S: 60-61
The full entry is committed at eu/32008R1272/CHANGELOG.md.